{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["EMT", "NSCLC", "TGF-\u03b21", "glycolysis", "pirfenidone"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "38140828", "DateCompleted": {"Year": "2024", "Month": "02", "Day": "09"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "12", "Day": "23"}], "Language": ["eng"], "ELocationID": ["e18059", "10.1111/jcmm.18059"], "Journal": {"ISSN": "1582-4934", "JournalIssue": {"Volume": "28", "Issue": "3", "PubDate": {"Year": "2024", "Month": "Feb"}}, "Title": "Journal of cellular and molecular medicine", "ISOAbbreviation": "J Cell Mol Med"}, "ArticleTitle": "Pirfenidone inhibits TGF-\u03b21-induced metabolic reprogramming during epithelial-mesenchymal transition in non-small cell lung cancer.", "Pagination": {"StartPage": "e18059", "MedlinePgn": "e18059"}, "Abstract": {"AbstractText": ["Metastasis is an important contributor to increased mortality rates in non-small cell lung cancer (NSCLC). The TGF-\u03b2 signalling pathway plays a crucial role in facilitating tumour metastasis through epithelial-mesenchymal transition (EMT). Glycolysis, a key metabolic process, is strongly correlated with NSCLC metastasis. Pirfenidone (PFD) has been shown to safely and effectively inhibit TGF-\u03b21 in patients with lung diseases. Furthermore, TGF-\u03b21 and glycolysis demonstrate an interdependent relationship within the tumour microenvironment. Our previous study demonstrated that PFD effectively inhibited glycolysis in NSCLC cells, prompting further investigation into its potential antitumour effects in this context. Therefore, the present study aims to investigate the potential antitumour effect of PFD in NSCLC and explore the relationship among TGF-\u03b21, glycolysis and EMT through further experimentation. The antitumour effects of PFD were evaluated using five different NSCLC cell lines and a xenograft tumour model. Notably, PFD demonstrated a significant antitumour effect specifically in highly glycolytic H1299 cells. To elucidate the underlying mechanism, we compared the efficacy of PFD after pretreatment with either TGF-\u03b21 or a TGF-\u03b2 receptor inhibitor (LY2109761). The energy metabolomics analysis of tumour tissue demonstrated that PFD, a chemosensitizing agent, reduced lactate and ATP production, thereby inhibiting glycolysis and exerting synergistic antineoplastic effects. Additionally, PFD combined with cisplatin targeted TGF-\u03b21 to inhibit glycolysis during EMT and enhanced the chemosensitization of A549 and H1299 cells. The magnitude of the anticancer effect exhibited by PFD was intricately linked to its metabolic properties."], "CopyrightInformation": "\u00a9 2023 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd."}, "AuthorList": [{"Identifier": ["0000-0003-1809-276X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Research Center of Food Nutrition and Health, Guizhou Medical University, Guiyang, China."}], "LastName": "Zhang", "ForeName": "Shuling", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guiyang, China."}], "LastName": "Wang", "ForeName": "Yuanmei", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Medical University, Guiyang, China."}], "LastName": "Luo", "ForeName": "Daiqin", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Medical University, Guiyang, China."}], "LastName": "Cheng", "ForeName": "Zhimei", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Research Center of Food Nutrition and Health, Guizhou Medical University, Guiyang, China."}], "LastName": "Zeng", "ForeName": "Qibing", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Research Center of Food Nutrition and Health, Guizhou Medical University, Guiyang, China."}], "LastName": "Wang", "ForeName": "Guoze", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Medical University, Guiyang, China."}], "LastName": "Chen", "ForeName": "Mengxue", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guiyang, China."}], "LastName": "Zhang", "ForeName": "Shuai", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, School of Public Health, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Provincial Engineering Research Center of Food Nutrition and Health, Guizhou Medical University, Guiyang, China."}], "LastName": "Luo", "ForeName": "Peng", "Initials": "P"}], "GrantList": [{"GrantID": "YJSKYJJ [2021] 158", "Agency": "Daiqin Luo", "Country": ""}, {"GrantID": "81660835", "Agency": "Peng Luo", "Country": ""}, {"GrantID": "FAMP2022Z3-3", "Agency": "Peng Luo", "Country": ""}, {"GrantID": "YJSKYJJ[2021] 149", "Agency": "Shuling Zhang", "Country": ""}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Cell Mol Med", "NlmUniqueID": "101083777", "ISSNLinking": "1582-1838"}, "ChemicalList": [{"RegistryNumber": "D7NLD2JX7U", "NameOfSubstance": "pirfenidone"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyridones"}, {"RegistryNumber": "0", "NameOfSubstance": "Transforming Growth Factor beta1"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["pathology"], "DescriptorName": "Carcinoma, Non-Small-Cell Lung"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": [], "DescriptorName": "Cell Movement"}, {"QualifierName": [], "DescriptorName": "Epithelial-Mesenchymal Transition"}, {"QualifierName": ["pathology"], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": [], "DescriptorName": "Metabolic Reprogramming"}, {"QualifierName": [], "DescriptorName": "Pyridones"}, {"QualifierName": ["metabolism"], "DescriptorName": "Transforming Growth Factor beta1"}, {"QualifierName": [], "DescriptorName": "Tumor Microenvironment"}, {"QualifierName": [], "DescriptorName": "Animals"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201048.", "ArticleIdList": ["36633525"]}, {"Citation": "Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non\u2010small\u2010cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535\u2010546.", "ArticleIdList": ["PMC5712844", "25056707"]}, {"Citation": "Lin S, Li Y, Wang D, et\u00a0al. Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression. Cancer Lett. 2021;518:230\u2010242.", "ArticleIdList": ["PMC8355190", "34303764"]}, {"Citation": "Zlack\u00e1 J, Zeman M. Glycolysis under circadian control. Int J Mol Sci. 2021;22(24):13666.", "ArticleIdList": ["PMC8703893", "34948470"]}, {"Citation": "Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325\u2010337.", "ArticleIdList": ["21508971"]}, {"Citation": "Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891\u2010899.", "ArticleIdList": ["15516961"]}, {"Citation": "Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029\u20101033.", "ArticleIdList": ["PMC2849637", "19460998"]}, {"Citation": "Ubellacker JM, Morrison SJ. Metabolic adaptation fuels lymph node metastasis. Cell Metab. 2019;29(4):785\u2010786.", "ArticleIdList": ["30943388"]}, {"Citation": "Kim J, DeBerardinis RJ. Mechanisms and implications of metabolic heterogeneity in cancer. Cell Metab. 2019;30(3):434\u2010446.", "ArticleIdList": ["PMC6730674", "31484055"]}, {"Citation": "Hensley CT, Faubert B, Yuan Q, et\u00a0al. Metabolic heterogeneity in human lung tumors. Cell. 2016;164(4):681\u2010694.", "ArticleIdList": ["PMC4752889", "26853473"]}, {"Citation": "Fendt SM, Frezza C, Erez A. Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer Discov. 2020;10(12):1797\u20101807.", "ArticleIdList": ["PMC7710573", "33139243"]}, {"Citation": "Thomas LW, Stephen JM, Esposito C, et\u00a0al. CHCHD4 confers metabolic vulnerabilities to tumour cells through its control of the mitochondrial respiratory chain. Cancer & Metabolism. 2019;7:2.", "ArticleIdList": ["PMC6404347", "30886710"]}, {"Citation": "Chuang CH, Dorsch M, Dujardin P, et\u00a0al. Altered mitochondria functionality defines a metastatic cell state in lung cancer and creates an exploitable vulnerability. Cancer Res. 2021;81(3):567\u2010579.", "ArticleIdList": ["PMC8137518", "33239425"]}, {"Citation": "Cruz\u2010Berm\u00fadez A, Laza\u2010Briviesca R, Vicente\u2010Blanco RJ, et\u00a0al. Cancer\u2010associated fibroblasts modify lung cancer metabolism involving ROS and TGF\u2010\u03b2 signaling. Free Radic Biol Med. 2019;130:163\u2010173.", "ArticleIdList": ["30391585"]}, {"Citation": "Ye Z, Zhang H, Kong F, et\u00a0al. Comprehensive analysis of alteration landscape and its clinical significance of mitochondrial energy metabolism pathway\u2010related genes in lung cancers. Oxid Med Cell Longev. 2021;2021:9259297.", "ArticleIdList": ["PMC8713050", "34970420"]}, {"Citation": "Goodgame B, Stinchcombe TE, Simon G, Wozniak A, Govindan R. Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009). J Thoracic Oncol. 2009;4(10):1293\u20101300.", "ArticleIdList": ["20197737"]}, {"Citation": "Knott SRV, Wagenblast E, Khan S, et\u00a0al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 2018;554(7692):378\u2010381.", "ArticleIdList": ["PMC5898613", "29414946"]}, {"Citation": "Li B, Qiu B, Lee DS, et\u00a0al. Fructose\u20101,6\u2010bisphosphatase opposes renal carcinoma progression. Nature. 2014;513(7517):251\u2010255.", "ArticleIdList": ["PMC4162811", "25043030"]}, {"Citation": "Huangyang P, Li F, Lee P, et\u00a0al. Fructose\u20101,6\u2010Bisphosphatase 2 inhibits sarcoma progression by restraining mitochondrial biogenesis. Cell Metab. 2020;31(1):174\u2010188.e7.", "ArticleIdList": ["PMC6949384", "31761563"]}, {"Citation": "Wang S, Fu JL, Hao HF, Jiao YN, Li PP, Han SY. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy. Pharmacol Res. 2021;170:105728.", "ArticleIdList": ["34119622"]}, {"Citation": "Li G, Ren J, Hu Q, et\u00a0al. Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF\u2010\u03b2 signaling in a murine colitis model. Biochem Pharmacol. 2016;117:57\u201067.", "ArticleIdList": ["27498142"]}, {"Citation": "Ying H, Fang M, Hang QQ, Chen Y, Qian X, Chen M. Pirfenidone modulates macrophage polarization and ameliorates radiation\u2010induced lung fibrosis by inhibiting the TGF\u2010\u03b21/Smad3 pathway. J Cell Mol Med. 2021;25(18):8662\u20108675.", "ArticleIdList": ["PMC8435416", "34327818"]}, {"Citation": "Marwitz S, Depner S, Dvornikov D, et\u00a0al. Downregulation of the TGF\u03b2 Pseudoreceptor BAMBI in non\u2010small cell lung cancer enhances TGF\u03b2 signaling and invasion. Cancer Res. 2016;76(13):3785\u20103801.", "ArticleIdList": ["27197161"]}, {"Citation": "Dey P, Kimmelman AC, DePinho RA. Metabolic Codependencies in the tumor microenvironment. Cancer Discov. 2021;11(5):1067\u20101081.", "ArticleIdList": ["PMC8102306", "33504580"]}, {"Citation": "Bauer Y, Tedrow J, de Bernard S, et\u00a0al. A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2015;52(2):217\u2010231.", "ArticleIdList": ["PMC4370242", "25029475"]}, {"Citation": "Mediavilla\u2010Varela M, Boateng K, Noyes D, Antonia SJ. The anti\u2010fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer\u2010associated fibroblasts. BMC Cancer. 2016;16:176.", "ArticleIdList": ["PMC4776434", "26935219"]}, {"Citation": "Kr\u00e4mer M, Markart P, Drakopanagiotakis F, et\u00a0al. Pirfenidone inhibits motility of NSCLC cells by interfering with the urokinase system. Cell Signal. 2020;65:109432.", "ArticleIdList": ["31693876"]}, {"Citation": "Qin W, Zou J, Huang Y, et\u00a0al. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD\u2010L1 blockade in mice. Onco Targets Ther. 2020;9(1):1824631.", "ArticleIdList": ["PMC7781712", "33457101"]}, {"Citation": "Yui Y, Kumai J, Watanabe K, Wakamatsu T, Sasagawa S. Lung fibrosis is a novel therapeutic target to suppress lung metastasis of osteosarcoma. Int J Cancer. 2022;151(5):739\u2010751.", "ArticleIdList": ["35342929"]}, {"Citation": "Wang G, Zhou X, Guo Z, et\u00a0al. The anti\u2010fibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF\u2010\u03b2. Cancer Biol Ther. 2022;23(1):150\u2010162.", "ArticleIdList": ["PMC8824226", "35130111"]}, {"Citation": "Es HA, Cox TR, Sarafraz\u2010Yazdi E, Thiery JP, Warkiani ME. Pirfenidone reduces epithelial\u2010mesenchymal transition and spheroid formation in breast carcinoma through targeting cancer\u2010associated fibroblasts (CAFs). Cancer. 2021;13(20):5118.", "ArticleIdList": ["PMC8533995", "34680267"]}, {"Citation": "Li D, Xia L, Huang P, et\u00a0al. Heterogeneity and plasticity of epithelial\u2010mesenchymal transition (EMT) in cancer metastasis: focusing on partial EMT and regulatory mechanisms. Cell Prolif. 2023;56:e13423.", "ArticleIdList": ["PMC10280150", "36808651"]}, {"Citation": "Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15(1):129.", "ArticleIdList": ["PMC9461252", "36076302"]}, {"Citation": "Antar SA, Saleh MA, Al\u2010Karmalawy AA. Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti\u2010inflammatory, anti\u2010fibrotic, anti\u2010oxidant, anti\u2010apoptotic, anti\u2010tumor, and/or anti\u2010SARS\u2010CoV\u20102. Life Sci. 2022;309:121048.", "ArticleIdList": ["PMC9536875", "36209833"]}, {"Citation": "Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi\u2010tool for tumor progression. EMBO J. 2021;40(18):e108647.", "ArticleIdList": ["PMC8441439", "34459003"]}, {"Citation": "Singh M, Yelle N, Venugopal C, Singh SK. EMT: mechanisms and therapeutic implications. Pharmacol Ther. 2018;182:80\u201094.", "ArticleIdList": ["28834698"]}, {"Citation": "Blaha CS, Ramakrishnan G, Jeon SM, et\u00a0al. A non\u2010catalytic scaffolding activity of hexokinase 2 contributes to EMT and metastasis. Nat Commun. 2022;13(1):899.", "ArticleIdList": ["PMC8850586", "35173161"]}, {"Citation": "Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201033.", "ArticleIdList": ["35020204"]}, {"Citation": "Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473.", "ArticleIdList": ["PMC7227780", "32273439"]}, {"Citation": "Faubert B, Li KY, Cai L, et\u00a0al. Lactate metabolism in human lung tumors. Cell. 2017;171(2):358\u2010371.e9.", "ArticleIdList": ["PMC5684706", "28985563"]}, {"Citation": "Liu JY, Wellen KE. Advances into understanding metabolites as signaling molecules in cancer progression. Curr Opin Cell Biol. 2020;63:144\u2010153.", "ArticleIdList": ["PMC7298879", "32097832"]}, {"Citation": "Lane AN, Tan J, Wang Y, Yan J, Higashi RM, Fan TW. Probing the metabolic phenotype of breast cancer cells by multiple tracer stable isotope resolved metabolomics. Metab Eng. 2017;43(Pt B):125\u2010136.", "ArticleIdList": ["PMC5540847", "28163219"]}, {"Citation": "Vanhove K, Graulus GJ, Mesotten L, et\u00a0al. The metabolic landscape of lung cancer: new insights in a disturbed glucose metabolism. Front Oncol. 2019;9:1215.", "ArticleIdList": ["PMC6873590", "31803611"]}, {"Citation": "L\u00fc\u00f6nd F, Tiede S, Christofori G. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. Br J Cancer. 2021;125(2):164\u2010175.", "ArticleIdList": ["PMC8292450", "33824479"]}, {"Citation": "H\u00f6nigova K, Navratil J, Peltanova B, Polanska HH, Raudenska M, Masarik M. Metabolic tricks of cancer cells. Biochim Biophys Acta Rev Cancer. 2022;1877(3):188705.", "ArticleIdList": ["35276232"]}, {"Citation": "Sayin VI, LeBoeuf SE, Papagiannakopoulos T. Targeting metabolic bottlenecks in lung cancer. Trends in Cancer. 2019;5(8):457\u2010459.", "ArticleIdList": ["31421901"]}, {"Citation": "Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009;124(3):511\u2010515.", "ArticleIdList": ["19003982"]}, {"Citation": "Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342\u2010348.", "ArticleIdList": ["11357141"]}, {"Citation": "Leal\u2010Esteban LC, Fajas L. Cell cycle regulators in cancer cell metabolism. Biochim Biophys Acta Mol Basis Dis. 2020;1866(5):165715.", "ArticleIdList": ["32035102"]}, {"Citation": "Marwitz S, Turkowski K, Nitschkowski D, et\u00a0al. The multi\u2010modal effect of the anti\u2010fibrotic drug Pirfenidone on NSCLC. Front Oncol. 2019;9:1550.", "ArticleIdList": ["PMC6985561", "32039023"]}, {"Citation": "Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of Antifibrotic medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):168\u2010174.", "ArticleIdList": ["31150266"]}, {"Citation": "Noble PW, Albera C, Bradford WZ, et\u00a0al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243\u2010253.", "ArticleIdList": ["PMC4697914", "26647432"]}, {"Citation": "Luo D, Zeng X, Zhang S, et\u00a0al. Pirfenidone suppressed triple\u2010negative breast cancer metastasis by inhibiting the activity of the TGF\u2010\u03b2/SMAD pathway. J Cell Mol Med. 2023;27(3):456\u2010469.", "ArticleIdList": ["PMC9889661", "36651490"]}, {"Citation": "Katz LH, Li Y, Chen JS, et\u00a0al. Targeting TGF\u2010\u03b2 signaling in cancer. Expert Opin Ther Targets. 2013;17(7):743\u2010760.", "ArticleIdList": ["PMC3745214", "23651053"]}, {"Citation": "Yin X, Choudhury M, Kang JH, et\u00a0al. Hexokinase 2 couples glycolysis with the profibrotic actions of TGF\u2010\u03b2. Sci Signal. 2019;12(612):eaax4067.", "ArticleIdList": ["31848318"]}, {"Citation": "Flum M, Dicks S, Teng YH, et\u00a0al. Canonical TGF\u03b2 signaling induces collective invasion in colorectal carcinogenesis through a Snail1\u2010 and Zeb1\u2010independent partial EMT. Oncogene. 2022;41(10):1492\u20101506.", "ArticleIdList": ["PMC8897192", "35075245"]}, {"Citation": "Xiao J, Sharma U, Arab A, et\u00a0al. Propagated circulating tumor cells uncover the potential role of NF\u03baB, EMT, and TGF\u03b2 signaling pathways and COP1 in metastasis. Cancer. 2023;15(6):1831.", "ArticleIdList": ["PMC10046547", "36980717"]}, {"Citation": "Hua W, Ten Dijke P, Kostidis S, Giera M, Hornsveld M. TGF\u03b2\u2010induced metabolic reprogramming during epithelial\u2010to\u2010mesenchymal transition in cancer. Cell Mol Life Sci. 2020;77(11):2103\u20102123.", "ArticleIdList": ["PMC7256023", "31822964"]}, {"Citation": "Rmaileh AA, Solaimuthu B, Tanna M, et\u00a0al. Large\u2010scale differential gene expression transcriptomic analysis identifies a metabolic signature shared by all cancer cells. Biomolecules. 2020;10(5):701.", "ArticleIdList": ["PMC7277211", "32365991"]}, {"Citation": "Sarmento\u2010Ribeiro AB, Scorilas A, Gon\u00e7alves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: clinical evidence. Drug Resist Updat. 2019;47:100646.", "ArticleIdList": ["31733611"]}, {"Citation": "Baghbani E, Noorolyai S, Rahmani S, et\u00a0al. Silencing tumor\u2010intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti\u2010tumoral effects of cisplatin: an in\u00a0vitro study. Biomed Pharmacother. 2022;145:112370.", "ArticleIdList": ["34862113"]}, {"Citation": "Zhang P, Li B, Chen Q, Wang H, Feng Q. Glucose restriction induces ROS\u2010AMPK\u2010mediated CTR1 expression and increases cisplatin efficiency in NSCLC. Cancer Lett. 2022;543:215793.", "ArticleIdList": ["35716782"]}, {"Citation": "Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168(4):657\u2010669.", "ArticleIdList": ["PMC5329766", "28187287"]}, {"Citation": "Tasdogan A, Faubert B, Ramesh V, et\u00a0al. Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 2020;577(7788):115\u2010120.", "ArticleIdList": ["PMC6930341", "31853067"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "11", "Day": "13"}, {"Year": "2023", "Month": "4", "Day": "13"}, {"Year": "2023", "Month": "11", "Day": "16"}, {"Year": "2024", "Month": "2", "Day": "8", "Hour": "6", "Minute": "43"}, {"Year": "2023", "Month": "12", "Day": "23", "Hour": "12", "Minute": "44"}, {"Year": "2023", "Month": "12", "Day": "23", "Hour": "3", "Minute": "33"}, {"Year": "2023", "Month": "12", "Day": "23"}], "PublicationStatus": "ppublish", "ArticleIdList": ["38140828", "PMC10844763", "10.1111/jcmm.18059"]}}], "PubmedBookArticle": []}